Hemophilia Treatment Drugs Market Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

Dec 2018| TMR426B| Transparency

Report Highlights

Hemophilia Treatment Drugs Market - Overview

Hemophilia treatment drugs are products that are administered into the patient’s body in order to replace the blood clotting factors that are missing in their blood so that the blood can clot properly.  This report analyzes the current and future prospects of the hemophilia treatment drugs market based on product type, disease indication, distribution channel, and region.  

The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of hemophilia treatment drugs market in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases. The report provides estimated market value in terms of US$ Mn for product type, disease indication, distribution channel, and region for the period 2018 to 2026.

The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on product type, disease indication, distribution channel, and region. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influences the hemophilia treatment drugs market in the current and future scenario. The report also provides Porter’s five force analysis that studies five factors and their impact on the hemophilia treatment drugs market.

Market share analysis among the market players is analyzed to signify the contribution of these players in the market in terms of percentage share. All these factors would help the market players to decide about the business strategies and plans to strengthen their positions in the global market. Based on region, the market has been analyzed for major regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The study also covers detailed country analysis in the respective regions for the hemophilia treatment drugs market.

The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the hemophilia treatment drugs market include Pfizer, Inc., CSL Behring, Kedrion, Shire Plc., Novo Nordisk A/S, Bayer AG, F. Hoffmann-La Roche Ltd., and Sanofi.

Strategic collaboration agreements and new product development was the primary strategy adopted by major market players to bolster their position in the hemophilia treatment drugs market.

The global hemophilia treatment drugs market has been segmented as follows:

Global Hemophilia Treatment Drugs Market, by Product Type
Recombinant coagulation factor concentrates
Factor VIII
Factor IX
Others
Plasma-derived coagulation factor concentrates
Factor VIII
Factor IX
Others
Others
Global Hemophilia Treatment Drugs Market, by Disease Indication
Hemophilia A
Hemophilia B
Others
Global Hemophilia Treatment Drugs Market, by Distribution Channel
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Hemophilia Treatment Drugs Market, by Region
North America
U.S.
Canada
Europe
U.K.
Germany
France
Spain
Italy
Rest of Europe
Asia Pacific
India
China
Japan
Australia & New Zealand
Rest of Asia Pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
South Africa
GCC countries
Rest of MEA

  • Table 1 : Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
  • Table 2 : Global Hemophilia Treatment Drugs Market Value (US$ Mn) Forecast, by Recombinant Coagulation Factor Concentrates, 2016–2026
  • Table 3 : Global Hemophilia Treatment Drugs Market Value (US$ Mn) Forecast, by Plasma derived coagulation factor concentrates, 2016–2026
  • Table 4 : Global Hemophilia Treatment Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
  • Table 5 : Global Hemophilia Treatment Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 6 : North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country, 2016–2026
  • Table 7 : North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
  • Table 8 : North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
  • Table 9 : North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 10 : Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 11 : Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
  • Table 12 : Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
  • Table 13 : Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 14 : Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 15 : Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
  • Table 16 : Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
  • Table 17 : Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 18 : Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 19 : Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
  • Table 20 : Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
  • Table 21 : Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Table 22 : Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
  • Table 23 : Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Product Type, 2016–2026
  • Table 24 : Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
  • Table 25 : Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast, by Distribution Channel, 2016–2026
  • Figure 1 : Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Size, by Product Type (US$ Mn), 2017
  • Figure 2 : Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Share Analysis by Region, 2017
  • Figure 3 : Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Opportunity Map, by Product Type
  • Figure 4 : Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Opportunity Map, by Disease Indication
  • Figure 5 : Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others)Market Opportunity Map, by Distribution Channel
  • Figure 6 : Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
  • Figure 7 : Global Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
  • Figure 8 : Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Recombinant coagulation factor concentrates, 2016–2026
  • Figure 9 : Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Plasma-derived coagulation factor concentrates, 2016–2026
  • Figure 10 : Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
  • Figure 11 : Global Bispecific & Next Generation Recombinant Products Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
  • Figure 12 : Global Gene Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
  • Figure 13 : Global Hemophilia Treatment Drugs Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 14 : Global Hemophilia Treatment Drugs Market Value Share, by Disease Indication, 2017 and 2026
  • Figure 15 : Global Hemophilia Treatment Drugs Market Attractiveness, by Disease Indication, 2018–2026
  • Figure 16 : Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Hemophilia A, 2016–2026
  • Figure 17 : Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Hemophilia B, 2016–2026
  • Figure 18 : Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Others, 2016–2026
  • Figure 19 : Global Hemophilia Treatment Drugs Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 20 : Global Hemophilia Treatment Drugs Market Attractiveness, by Distribution Channel, 2018–2026
  • Figure 21 : Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2016–2026
  • Figure 22 : Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2016–2026
  • Figure 23 : Global Hemophilia Treatment Drugs Market Value (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2016–2026
  • Figure 24 : North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
  • Figure 25 : North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country, 2017 and 2026
  • Figure 26 : North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country, 2018–2026
  • Figure 27 : North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
  • Figure 28 : North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
  • Figure 29 : North America Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
  • Figure 30 : North America Gene Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
  • Figure 31 : North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
  • Figure 32 : North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018–2026
  • Figure 33 : North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 34 : North America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018–2026
  • Figure 35 : Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
  • Figure 36 : Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country/Sub-region, 2017 and 2026
  • Figure 37 : Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country/Sub-region, 2018–2026
  • Figure 38 : Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
  • Figure 39 : Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
  • Figure 40 : Europe Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
  • Figure 41 : Europe Gene Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
  • Figure 42 : Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
  • Figure 43 : Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018–2026
  • Figure 44 : Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 45 : Europe Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018–2026
  • Figure 46 : Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
  • Figure 47 : Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country/Sub-region, 2017 and 2026
  • Figure 48 : Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country/Sub-region, 2018–2026
  • Figure 49 : Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
  • Figure 50 : Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
  • Figure 51 : Asia Pacific Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
  • Figure 52 : Asia Pacific Gene Therapy Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
  • Figure 53 : Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
  • Figure 54 : Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018–2026
  • Figure 55 : Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 56 : Asia Pacific Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018–2026
  • Figure 57 : Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
  • Figure 58 : Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country/Sub-region, 2017 and 2026
  • Figure 59 : Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country/Sub-region, 2018–2026
  • Figure 60 : Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
  • Figure 61 : Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
  • Figure 62 : Latin America Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
  • Figure 63 : Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
  • Figure 64 : Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018–2026
  • Figure 65 : Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 66 : Latin America Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018–2026
  • Figure 67 : Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
  • Figure 68 : Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Country/Sub-region, 2017 and 2026
  • Figure 69 : Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Country/Sub-region, 2018–2026
  • Figure 70 : Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Product Type, 2017 and 2026
  • Figure 71 : Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Product Type, 2018–2026
  • Figure 72 : Middle East & Africa Bispecific & Next Generation Recombinant Factor Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2018–2026
  • Figure 73 : Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Disease Indication, 2017 and 2026
  • Figure 74 : Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Disease Indications, 2018–2026
  • Figure 75 : Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Value Share, by Distribution Channel, 2017 and 2026
  • Figure 76 : Middle East & Africa Hemophilia Treatment Drugs (Recombinant Factor, Plasma Derived, & Others) Market Attractiveness, by Distribution Channel, 2018–2026

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
Share This Report